Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders

Leukemia and Lymphoma

Volumn 46, Issue 10, 2005, Pages 1397-1407

  Muti, Giuliana ^a   Mancini, V ^a   Ravelli, E ^a   Morra, E ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

EBV; IL 10; Lymphoma; Post transplant; PTLD

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; RITUXIMAB; VIRUS DNA;

CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FOLLOW UP; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; INTERLEUKIN-10; LYMPHOPROLIFERATIVE DISORDERS; STEM CELL TRANSPLANTATION; VIRAL LOAD;

EID: 26944490734     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500160272     Document Type: Review

References (92)

1. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Seminars in Diagnostic Pathology 1997;14:8-14.
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clincal Advisory Committee Meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology 1999;17:3835-3849.
3. Middeldorp JM, Brink AATP, Van den Brule AJC, Meijer CJLM. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Critical Reviews in Oncology Hematology 2003;45:1-36.
4. Tsai DE, Nearey M, Hardy CL, Tomaszewski JE, Kotloff RM, Grossman RA, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. American Journal of Transplantation 2002;2:946-954.
5. Stevens SJC, Verschuuren EAM, Verkuijlen SAW, van den Brule AJC, Meijer CJLM, Middeldorp JM. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leukemia and Lymphoma 2002;43:831-840.
6. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumors. Oncogene 2003;22:5108-5121.
7. Birkeland SA, Bendtzen K, Moller B, Hamilton Dutoit S, Andersen HK. Transplantation 1999;67:876-881.
8. Garnier JL, Blanc Brunat N, Vivier G, Rousset F, Touraine JL. Interleukin-10 in Epstein-Barr virus-associated posttransplant lymphomas. Clinical Transplantation 1999;13: 305-312.
9. Wagner HJ, Fischer L, Jabbs WJ, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002;74:656-664.
10. Preiksaitis JK. New developments in the diagnosis and menagement of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clinical Infectious Diseases 2004;39:1016-1023.
11. Allen U, Hebert D, Petric M, Tellier R, Tran D, Superina R, et al. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clinical Infectious Diseases 2001;33: 145-150.
12. Gartner BC, Schafer H, Marggraff K, Eisele G, Schafer M, Roemer K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogenic stem cell transplantation to diagnose and monitor postransplant lymphoproliferative disease. Journal of Clinical Microbiology 2002;40:351-358.
13. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998;91:3654-3661.
14. Fellner MD, Durand K, Correa M, Bes D, Alonio LV, Teyssie AR, et al. A semiquantitative PCR method (SQ-PCR) to measure Epstein-Barr virus (EBV) load: its application in transplant patients. Journal of Clinical Virology 2003;28:323-330.
15. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. Journal of Clinical Microbiology 1999;37:132-136.
16. Niesters HGM, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus ADME. Development of a real-time quantitative assay for detection of Epstein-Barr virus. Journal of Clinical Microbiology 2000;38:712-715.
17. Jabs WJ, Hennig H, Kittel M, Pethig K, Smets F, Bucsky P, et al. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. Journal of Clinical Microbiology 2001;39:564-569.
18. Stevens SJC, Verkuijlen SAWM, van den Brule AJC, Middeldrop JM. Comparison of quantitative competitive PCR with lightcycler-based PCR for measuring Epstein-Barr virus DNA load inclinical specimens. Journal of Clinical Microbiology 2002;40:3986-3992.
19. Leung E, Shenton BK, Jackson G, Could FK, Yap C, Talbot D. Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood. Journal of Immunological Methods 2002;270:259-267.
20. Brengel-Pesce K, Morand P, Schmuck A, Bourgeat MJ, Buisson M, Bargues G, et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. Journal of Medical Virology 2002;66:360-369.
21. Matsukura T, Yokoi A, Egawa H, Kudo T, Kawashima M, Hirata Y, et al. Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation. Clinical Transplantation 2002;16:107-112.
22. Meerbach A, Gruhn B, Egerer R, Reischl U, Zintl F, Wutzler P. Semiquantitative PCR analysis of Epstein-Barr virus DNA in clinical samples of patients with EBV-associated diseases. Journal of Medical Virology 2001;65:348-357.
23. Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, et al. Use of quantitative competitive PCR to measure Epstein-Barr Virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. Journal of Clinical Microbiology 1997;35:1612-1615.
24. Mutimer D, Kaur N, Tang H, Singhal S, Shaw J, Whitehead L, et al. Quantification of Epstein-Barr virus DNA in the blood of adult liver transplant recipients. Transplantation 2000;69:954-959.
25. Stevens SJC, Pronk I, Middeldrop JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. Journal of Clinical Microbiology 2001;39:1211-1216.
26. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transplant Infectious Disease 2001;3:79-87.
27. van Esser M, Niesters HGM, van der Holt B, Meijer E, Osterhaus ADME, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogenic stem cell transplantation. Blood 2002;99:4364-4369.
28. Campe H, Jaeger G, Abou-Ajram C, Nitschko H, Griebel M, Montoya C, et al. Serial detection of Epstein-Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosis-like symptoms defines patients at risk to develop post-transplant lymphoproliferative disease. Pediatric Transplantation 2003;7:46-52.
29. Orii T, Ohkohchi N, Kikuchi H, Koyamada N, Chubachi S, Satomi S, et al. Usfulness of quantitative real-time polymerase chain reaction in following up patients with Epstein-Barr virus infection after liver transplantation. Clinical Transplantation 2000;14:308-317.
30. Limaye AP, Huang M-L, Atienza EE, Ferrenberg JM and Corey L. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. Journal of Clinical Microbiology 1999;37:1113-1116.
31. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Ruutu T, Mattila PS, et al. Lymphoproliferative disease after allogenic stem cell transplantation-pre-emtive diagnosis by quantification of Epstein-Barr virus DNA in serum. Journal of Clinical Virology 2003;28:275-2-83.
32. Sirvent-von Bueltzingsloewen A, Morand P, Buisson M, Souillet G, Chambost H, Bosson JL, Bordigoni P. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplantation 2002;29:21-28.
33. Stevens SJC, Verschuuren EAM, Pronk I, Van der Bij W, Harmsen MC, The TH, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001;97:1165-1171.
34. Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, et al. Epstein-Barr virus (EBV) reactivation in allogenic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004;77:76-84.
35. Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: diseapparance after rituximab therapy does not predict clinical response. Blood 2000;96:4055-4063.
36. Green M, Webber SA. EBV viral load monitoring: unanswered questions. American Journal of Transplantation 2002;2:894-895.
37. Heslop H, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Practice & Research Clinical Haematology 2004; 17:401-413.
38. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatric Transplantation 2002;6:456-464.
39. van Esser JWJ, van der Holt B, Meijer E, Niesters HGM, Trenschel R, Thijsen SFT, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogenic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-978.
40. Orentas RJ, Schauer DW Jr, Ellis FW, Walczak J, Casper JT, Margolis DA. Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatric Transplantation 2003;7:305-314.
41. Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the preemptive management of Epstein-Barr virus reactivation after allogenic haematopoietic stem cell transplantation. British Journal of Haematology 2004;128:224-233.
42. Green M, Bueno J, Rowe D, Mazariegos G, Qu L, Abu-Almagd K, Reyes J. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000;70:593-596.
43. Scheenstra R, Verschuuren EAM, de Haan A, Slooff MJH, The TH, Bijleveld CMA, Verkade HJ. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transplant Infectious Disease 2004;6:15-22.
44. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002;74:367-372.
45. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994;83:2715-2722.
46. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM. Ratio between Epstein-Barr viral load ant anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002;73:1603-1610.
47. Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. Journal of Infectious Disease 2003;188:1853-1864.
48. Vossen MTM, Gent MR, Davin JC, Baars PA, Wertheim-van Dillen PME, Weel JFL, et al. Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients. Transplant International 2004;17:89-96.
49. Baudouin V, Dehee A, Pedron-Grossetete B, Ansart-Pirenne H, Haddad E, Maisin A, et al. Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study. Transplantation 2004;77:1706-1713.
50. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders. A distinct entity? American Journal of Surgical Pathology 2000;24:375-385.
51. Muti G, Klersy C, Baldanti F, Granata S, Oreste P, Pezzetti L, et al. Epstein-Barr virus (EBV) laod and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. British Journal of Haematology 2003;122:927-933.
52. Axelrod DA, Holmes R, Thomas SE, Magee JC. Limitations of EBV-PCR monitorino to detect EBV associated posttransplant lymphoproliferative disorder. Pediatric Transplantation 2003;7:223-227.
53. Nuckols JD, Baron PW, Stenzel TT, Olatidoye BA, Tuttle-Newhall JE, Clavien P-A, et al. The pathology of liver-localized post-transplant lymphoproliferative disease. A report of three cases and a review of the literature. American Journal of Surgical Pathology 2000;24:733-741.
54. Muti G, Mancini V, Veronese S, Poli F, Oreste P, Baldanti F, et al. Donor or recipient origin of posttransplant lymphoproliferative disorders in liver transplanted patients: two different, clinically relevant, patterns of disease. Blood 2003;102:Abstract 2324.
55. Baldanti F, Grossi P, Furione M, Simoncini L, Sarasini A, Comoli P, et al. High levels of Epstein-Barr virus DANN in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. Journal of Clinical Microbiology 2000;38:613-619.
56. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Posttransplant lymphoproliferative disorder: a review. Bone Marrow Transplantation 2003;31:145-155.
57. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. Journal of Experimental Medicine 1999;190:567-576.
58. Hopwood PA, Brooks L, Parratt R, Hunt BJ, Maria B, Alero BJ, et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healty immunosuppressed transplant recipients. Transplantation 2002;74:194-202.
59. Vajro P, Lucariello S, Migliaro F, Sokal E, Gridelli B, Vegnente A, et al. Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. The Journal of Infectious Diseases 2000;181:2050-2054.
60. Randhawa PS, Demetris AJ, Nalesnik MA. The potential role of cytokines in the pathogenesis of Epstein-Barr virus associated post-transplant lymphoproliferative disease. Leukemia and Lymphoma 1994;15:383-387.
61. Tosato G, Teruya Feldstein J, Setsuda J, Pike SE, Jones KD, Jaffe ES. Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Springer Seminars in Immunpathology 1998;20:405-423.
62. Ohga S, Nomura A, Takada H, Hara T. Immunological aspects of Epstein-Barr virus infection. Critical Reviews in Oncology/Hematology 2002;44:203-215.
63. Nalesnik MA, Zeevi A, Randhawa PS, Faro A, Spichty KJ, Demetris AJ, et al. Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clinical Transplantation 1999;13:39-44.
64. Tanner JE, Alfieri C. The Epstein-Barr virus and posttransplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transplant Infectious Disease 2001;3:60-69.
65. Voorzanger N, Blay JY. Interleukin 10 and Hodgkin's lymphomas. In: Touraine JI, Traeger J, Betuel H, Dubrenand JM, Revillard JP, Dupuy C., editors. Cancer in transplantation. Prevention and treatment. Dordrecht: Kluwer Academic Publisher; 1996. p 229-241.
66. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends in Immunology 2003;24:36-43.
67. Burdin N, Rousset F, Banchereau J. B-cell-derived IL-10: production and function. Methods 1997;11:98-111.
68. Bejarano MT, Masucci MG. Interleukin-10 abrogates the inibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood 1998;92:4256-4262.
69. Mahot S, Sergeant A, Drouet E, Gruffat H. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. Journal of General Virology 2003;84:965-974.
70. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? The Journal of Immunology 2004;172:3422-3427.
71. Hayes DP, Brink AATP, Vervoort MBHJ, Middeldorp JM, Meijer CJLM, van den Brule AJC. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Journal of Clinical Pathology: Molecular Pathology 1999;52:97-103.
72. Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends in Immunology 2002;23:89-96.
73. Ryon JJ, Hayward SD, MacMahon EME, Mann RB, Ling Y, Charache P, et al. In situ detection of lytic Epstein-Barr virus infection: expression of the NotI early gene and viral interleukin-10 late gene in clinical specimens. The Journal of Infectious Diseases 1993;168:345-351.
74. Kitagawa N, Goto M, Kurozumi K, Maruo S, Fukayama M, Naoe T, et al. Epstein-Barr virus-encoded poly(A)-RNA supports Burkitt's lymphoma growth through interleukin-10 induction. The EMBO Journal 2000;19:6742-6750.
75. Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H, et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996;87:2918-2929.
76. Dukers DF, Jaspars LH, Vos W, Oudejans JJ, Hayes D, Cillessen S, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. Journal of Pathology 2000;190:143-149.
77. Ohga S, Nomura A, Takada H, Tanaka T, Furuno K, Takahata Y, et al. Dominant expression of interleukin-10 and transforming growth factor-β genes in activated T-cells of chronic active Epstein-Barr virus infection. Journal of Medical Virology 2004;74:449-458.
78. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leukemia and Lymphoma 1997;26:251-259.
79. Breen CE, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clinical Immunology 2003;109:119-129.
80. Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Tosato G. Viral interleukin-10 in chronic active Epstein-Barr virus infection. The Journal of Infectious Disease 1997;176:254-257.
81. Xu ZG, Iwatsuki K, Oyama N, Ohtsuka M, Satoh M, Kikuchi S, et al. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. British Journal of Cancer 2001;84:920-925.
82. Beck A, Pazolt D, Grabenbauer GG, Nicholls JM, Herbst H, Young LS, et al. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasooharyngeal carcinoma: comparison with Hodgkin's disease. Journal of Pathology 2001;194:145-151.
83. Herling M, Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Kliche KO, Nadali G, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clinical Cancer Research 2003;9:2114-2120.
84. Fassone L, Gaidano G, Ariatti C, Vivenza D, Capello D, Gloghini A, et al. The role of cytokines in the pathogenesis and management of Aids-related lymphomas. Leukemia and Lymphoma 2000;38:481-488.
85. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Annals of Oncology 1999;10: 433-440.
86. Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Annals of Hematology 2000;79:110-113.
87. Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Hematologica 2001;86:274-281.
88. Ozdemir F, Aydin F, Yilmaz M, Kavgaci H, Bektas O, Yavuz MN, Yavuz AA. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive non-Hodgkin's lymphoma (NHL). Journal of Experimental and Clinical Cancer Research 2004;23:485-488.
89. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. The Journal of Immunology 1997;158:4045-4051.
90. Hornef MW, Bein G, Wilhelm D, Fricke L, Kirchner H. ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation. Clinical and Diagnostic Laboratory Immunology 1997;4:545-549.
91. Muti G, Cantoni S, Rossi V, Granata S, D'Avanzo G, Pezzetti L, et al. IL-10 serum levels in lymphomas of immunocompromised and immunocompetent patients. The Hematology Journal 2001;I(Suppl I):Abstract 499.
92. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979-3981.